Multigene Assays for Classification, Prognosis, and Prediction in Breast Cancer: a Critical Review on the Background and Clinical Utility.
Gene signatures which are based on multigene profiling assays have been developed for the purpose to better define the prognosis and prediction of therapy results in early-stage breast cancer. These assays were designed to be more specific than conventional clinico-pathologic parameters in the selection of patients for (neo-)adjuvant treatment and in effect help to avoid unnecessary cytotoxic treatment. In this review we describe molecular risk scores, for which tests are commercially available (PAM50®, MammaTyper®, MammaPrint®, Oncotype DX®, Endopredict®, Genomic Grade Index®) and IHC risk scores (Mammostrat® and IHC4), and discuss the current evidence of their clinical use.
Department of Pathology, University of Heidelberg, Heidelberg.
P
P
Sinn
Department of Pathology, University of Heidelberg, Heidelberg.
S
S
Aulmann
Stratifyer Molecular Pathology GmbH, Köln.
R
R
Wirtz
Department of Gynaecology and Obstetrics, University of Heidelberg, Heidelberg.
S
S
Schott
Department of Gynaecology and Obstetrics, University of Heidelberg, Heidelberg.
F
F
Marmé
Institute of Surgical Pathology, University Hospital Zürich, Zürich, Switzerland.
Z
Z
Varga
Dept. of Pathology, University Medical Canter Hamburg-Eppendorf, Hamburg.
A
A
Lebeau
Institute of Pathology, Medizinische Hochschule Hannover, Hannover.
H
H
Kreipe
National Center of Tumor Diseases, Heidelberg.
A
A
Schneeweiss
breast cancer; multigene assays; prognosis